关注
Jeffrey W. Johannes
Jeffrey W. Johannes
在 astrazeneca.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
AE Tron, MA Belmonte, A Adam, BM Aquila, LH Boise, E Chiarparin, ...
Nature communications 9 (1), 5341, 2018
4612018
Photoredox mediated nickel catalyzed cross-coupling of thiols with aryl and heteroaryl iodides via thiyl radicals
MS Oderinde, M Frenette, DW Robbins, B Aquila, JW Johannes
Journal of the American Chemical Society 138 (6), 1760-1763, 2016
4062016
Current and future roles of artificial intelligence in medicinal chemistry synthesis
TJ Struble, JC Alvarez, SP Brown, M Chytil, J Cisar, RL DesJarlais, ...
Journal of medicinal chemistry 63 (16), 8667-8682, 2020
1882020
Highly Chemoselective Iridium Photoredox and Nickel Catalysis for the Cross‐Coupling of Primary Aryl Amines with Aryl Halides
MS Oderinde, NH Jones, A Juneau, M Frenette, B Aquila, S Tentarelli, ...
Angewandte Chemie 128 (42), 13413-13417, 2016
1792016
Effects of molecular oxygen, solvent, and light on iridium-photoredox/nickel dual-catalyzed cross-coupling reactions
MS Oderinde, A Varela-Alvarez, B Aquila, DW Robbins, JW Johannes
The Journal of Organic Chemistry 80 (15), 7642-7651, 2015
1012015
Structure based design of non-natural peptidic macrocyclic Mcl-1 inhibitors
JW Johannes, S Bates, C Beigie, MA Belmonte, J Breen, S Cao, ...
ACS medicinal chemistry letters 8 (2), 239-244, 2017
742017
Biomimetic Macrocycle-Forming Diels− Alder Reaction of an Iminium Dienophile: Synthetic Studies Directed Toward Gymnodimine
JW Johannes, S Wenglowsky, Y Kishi
Organic letters 7 (18), 3997-4000, 2005
692005
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper …
JW Johannes, A Balazs, D Barratt, M Bista, MD Chuba, S Cosulich, ...
Journal of Medicinal Chemistry 64 (19), 14498-14512, 2021
682021
Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper
G Illuzzi, AD Staniszewska, SJ Gill, A Pike, L McWilliams, SE Critchlow, ...
Clinical cancer research 28 (21), 4724-4736, 2022
632022
Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology
JW Johannes, L Almeida, B Barlaam, PA Boriack-Sjodin, R Casella, ...
ACS medicinal chemistry letters 6 (3), 254-259, 2015
602015
Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering
JW Johannes, L Almeida, K Daly, AD Ferguson, SE Grosskurth, H Guan, ...
Bioorganic & medicinal chemistry letters 25 (24), 5743-5747, 2015
592015
Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases
T Wang, MA Block, S Cowen, AM Davies, E Devereaux, L Gingipalli, ...
Bioorganic & medicinal chemistry letters 22 (5), 2063-2069, 2012
552012
A Unified and Practical Method for Carbon–Heteroatom Cross‐Coupling Using Nickel/Photo Dual Catalysis
RA Escobar, JW Johannes
Chemistry–A European Journal 26 (23), 5168-5173, 2020
522020
Structure‐based design of selective noncovalent CDK12 inhibitors
JW Johannes, CR Denz, N Su, A Wu, AC Impastato, S Mlynarski, ...
ChemMedChem 13 (3), 231-235, 2018
472018
Discovery and Optimization of a Novel Series of Potent Mutant B-RafV600E Selective Kinase Inhibitors
MM Vasbinder, B Aquila, M Augustin, H Chen, T Cheung, D Cook, L Drew, ...
Journal of Medicinal Chemistry 56 (5), 1996-2015, 2013
432013
Nickel-catalyzed photoredox-mediated cross-coupling of aryl electrophiles and aryl azides
MO Konev, TA McTeague, JW Johannes
ACS catalysis 8 (10), 9120-9124, 2018
422018
Pharmacological inhibition of PARP6 triggers multipolar spindle formation and elicits therapeutic effects in breast cancer
Z Wang, SE Grosskurth, T Cheung, P Petteruti, J Zhang, X Wang, W Wang, ...
Cancer research 78 (23), 6691-6702, 2018
402018
A Novel method for the direct synthesis of symmetrical and unsymmetrical sulfides and disulfides from aryl halides and ethyl potassium xanthogenate
M Soleiman-Beigi, Z Arzehgar
Synlett 29 (07), 986-992, 2018
322018
Free ligand 1D NMR conformational signatures to enhance structure based drug design of a Mcl-1 inhibitor (AZD5991) and other synthetic macrocycles
AYS Balazs, RJ Carbajo, NL Davies, Y Dong, AW Hird, JW Johannes, ...
Journal of Medicinal Chemistry 62 (21), 9418-9437, 2019
292019
Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers
AW Hird, JP Secrist, A Adam, MA Belmonte, E Gangl, F Gibbons, ...
Cancer Research 77 (13_Supplement), DDT01-02-DDT01-02, 2017
292017
系统目前无法执行此操作,请稍后再试。
文章 1–20